News

23andMe’s Former CEO Pushes Purchase Price Nearly $50 Million Higher
Me has a path to a higher purchase price than the $256 million offered by biotech giant Regeneron after the genetic-testing ...
You gave 23andMe your DNA. It may now transfer to a new company. | Opinion
A key decision by the bankruptcy judge could help with protecting consumer data, write Diane Lourdes Dick and Anya Prince.
23andMe finally closes the door on former headquarters
Is this tech company behind CEO's bid for 23andMe genetic data? How Anne Wojcicki's group still could snag 23andMe How Anne ...
23andMe sold out and sold your genetic info, no consent necessary
We’ve entered an era where biometric identity is currency. Regeneron just cornered a market without asking the public, the ...
STAT3dOpinion
I worked at 23andMe during its collapse. Here’s what the next consumer-genomics giant needs to understand
In trying to lead before the system could follow, 23andMe outpaced the very guardrails that might have legitimized it”: A ...
JD Supra14d
23andMe and the Role of Privacy in Bankruptcy Law
There is nothing more inherently unique and personal to an individual than his or her DNA. Unlike many other types of personal information, a ...
Rolling Out17d
The fall of 23andMe and what it means for your DNA
The $256 million sale price may resolve 23andMe’s immediate financial problems, but the broader questions about genetic privacy, consumer rights, and the commodification of biological ...
BioSpace17d
Regeneron Comes to 23andMe’s Rescue With $256M Acquisition Plan
DB-OTO, which Regeneron obtained from the 2023 acquisition of Decibel Therapeutics for $109 million, works by delivering a functioning copy of the otoferlin gene, one of the main causes of congenital ...